Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19488700 | 0.92 | CA12 (0.46) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL76577 | 0.88 | PAOX (0.57) | CYP2D6ALDH1A1SMN1; SMN2HPGDDUSP3 | |
| SCHEMBL4401738 | 0.86 | CA12 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL13520192 | 0.85 | TSHR (0.49) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL22317835 | 0.84 | PAOX (0.58) | CYP2D6ALDH1A1SMN1; SMN2HPGDDUSP3 | |
| SCHEMBL4783223 | 0.84 | ACE2 (0.54) | TSHRSMN1; SMN2KDM1A | |
| SCHEMBL19488701 | 0.82 | CA12 (0.39) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL13912969 | 0.82 | PAOX (0.51) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL926464 | 0.80 | TSHR (0.45) | CA12CA1CA2CA9CYP2D6 | |
| SCHEMBL5430626 | 0.79 | PRMT6 (0.58) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118879293-A | Degradable nano silicon dioxide oil displacement agent with surface activity and application thereof | 中国海洋石油集团有限公司 | 2024-11-01 | — | — | CN | claimed |
| CN-120718485-A | Water-based epoxy resin auxiliary agent, preparation method and application thereof | 上海长链新材料科技有限公司 | 2025-09-30 | — | — | CN | disclosed |
| CN-118879293-A | Degradable nano silicon dioxide oil displacement agent with surface activity and application thereof | 中国海洋石油集团有限公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4393922-A1 | IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-5409913-A | Renin inhibitors | Keane, J. Timothy (US) | 1995-04-25 | — | — | US | disclosed |
| US-5409945-A | Benzyo-fused thiazolidinyl terminated alkylamino ethylnyl alanine amino diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1995-04-25 | — | — | US | disclosed |
| US-5409921-A | Renin inhibitors | G. D. SEARLE & CO. (US) | 1995-04-25 | — | — | US | disclosed |
| US-5409924-A | Renin inhibitors | G. D. SEARLE & CO. (US) | 1995-04-25 | — | — | US | disclosed |
| US-5348953-A | Elastase inhibitor | MERCK & CO., INC. (US) | 1994-09-20 | — | — | US | disclosed |
| WO-1994004518-A1 | MORPHOLINO/THIOMORPHOLINO-TERMINATED ALKYLAMINO ETHYNYL ALANINE AMINO DIOL COMPOUNDS AS RENIN INHIBITORS | G.D. SEARLE & CO. (US) | 1994-03-03 | — | — | WO | disclosed |
| WO-1990006928-A1 | 6-(1-CARBAMOYL-1-HYDROXYMETHYL)PENICILLANIC ACID DERIVATIVES | BARTH WAYNE E (US) | 1990-06-28 | — | — | WO | disclosed |
| US-4868296-A | 6-(1-carbamoyl-1-hydroxymethyl) penicillanic acid derivatives | PFIZER INC. (US) | 1989-09-19 | — | — | US | disclosed |
| US-4797394-A | 6-(1-carbamoyl-1-hydroxymethyl)penicillanic acid derivatives | PFIZER INC. (US) | 1989-01-10 | — | — | US | disclosed |
| EP-0220939-A1 | 6-(1-Carbamoyl-1-hydroxymethyl)penicillanic-acid derivatives | PFIZER INC. (US) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CA12 4761/4885CA1 4833/4885CA2 4689/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CA12 3267/4885CA1 3083/4885CA2 1016/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | CA12 3267/4885CA1 3083/4885CA2 1016/4885 |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | MIF, MMP12, METAP1 | CA12 1554/4885CA1 1097/4885CA2 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.